Literature DB >> 24573920

An investigation of the stability of emerging new psychoactive substances.

Yan Ni Annie Soh1, Simon Elliott.   

Abstract

The evolving nature of new psychoactive substances (NPS) - often referred to as 'legal highs', 'designer drugs' or 'bath salts' - presents an evolving challenge for toxicologists. Apart from the detection and identification of these compounds, further analytical challenges may arise from the presence of possible metabolites or degradation products which may have to be considered when devising an analytical strategy. Whilst there has been some stability research for some more established drugs of abuse and medicinal products, data on emerging NPS are less abundant. In order to address this need, 13 NPS (4-MEC, MDAI, methoxetamine, 5-MeO-DALT, 6-APB, MPA, 5-IAI, MDAT, 2-AI, AMT, 25C-NBOMe, AH-7921, 5-MAPB) were spiked in blood and plasma and kept at room temperature (20-23 °C). Detection and identification of the suspected breakdown products were carried out by high performance liquid chromatography with diode-array detection (HPLC-DAD), liquid chromatography-tandem mass spectrometry (LC-MS/MS), and ultra high performance liquid chromatography with high mass accuracy quadrupole time-of-flight mass spectrometry (UHPLC-Q-TOF-MS). 4-MEC became undetectable in blood within 14 days with a corresponding loss of 54% in plasma. A breakdown product was identified as dihydro-4-MEC which was also found in vivo in a case work sample. Storage of AMT led to a range of potential breakdown products which were also found in vivo. The remaining substances were found to be stable for at least 21 days in blood and plasma. This is the first time stability data have been published for these emerging substances and showed that additional compounds found during forensic casework were potential metabolites rather than instability products. In particular, presumptive metabolites of 25C-NBOMe and AH-7921 are presented.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  blood; designer drugs; new psychoactive substances; plasma; stability

Mesh:

Substances:

Year:  2013        PMID: 24573920     DOI: 10.1002/dta.1576

Source DB:  PubMed          Journal:  Drug Test Anal        ISSN: 1942-7603            Impact factor:   3.345


  10 in total

1.  Metabolic characterization of AH-7921, a synthetic opioid designer drug: in vitro metabolic stability assessment and metabolite identification, evaluation of in silico prediction, and in vivo confirmation.

Authors:  Ariane Wohlfarth; Karl B Scheidweiler; Shaokun Pang; Mingshe Zhu; Marisol Castaneto; Robert Kronstrand; Marilyn A Huestis
Journal:  Drug Test Anal       Date:  2015-09-01       Impact factor: 3.345

2.  Validation of the only commercially available immunoassay for synthetic cathinones in urine: Randox Drugs of Abuse V Biochip Array Technology.

Authors:  Kayla N Ellefsen; Sébastien Anizan; Marisol S Castaneto; Nathalie A Desrosiers; Thomas M Martin; Kevin L Klette; Marilyn A Huestis
Journal:  Drug Test Anal       Date:  2014-03-21       Impact factor: 3.345

3.  Analytical characterization of N,N-diallyltryptamine (DALT) and 16 ring-substituted derivatives.

Authors:  Simon D Brandt; Pierce V Kavanagh; Geraldine Dowling; Brian Talbot; Folker Westphal; Markus R Meyer; Hans H Maurer; Adam L Halberstadt
Journal:  Drug Test Anal       Date:  2016-04-21       Impact factor: 3.345

Review 4.  Clinical value of analytical testing in patients presenting with new psychoactive substances intoxication.

Authors:  Katharina Elisabeth Grafinger; Matthias E Liechti; Evangelia Liakoni
Journal:  Br J Clin Pharmacol       Date:  2019-12-17       Impact factor: 4.335

5.  A Quantitative LC-MS/MS Method for the Detection of 16 Synthetic Cathinones and 10 Metabolites and Its Application to Suspicious Clinical and Forensic Urine Samples.

Authors:  Abdulaziz A Aldubayyan; Erika Castrignanò; Simon Elliott; Vincenzo Abbate
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-22

6.  Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD).

Authors:  Simon D Brandt; Pierce V Kavanagh; Folker Westphal; Alexander Stratford; Simon P Elliott; Khoa Hoang; Jason Wallach; Adam L Halberstadt
Journal:  Drug Test Anal       Date:  2015-10-12       Impact factor: 3.345

7.  AH-7921: the list of new psychoactive opioids is expanded.

Authors:  Maria Katselou; Ioannis Papoutsis; Panagiota Nikolaou; Chara Spiliopoulou; Sotiris Athanaselis
Journal:  Forensic Toxicol       Date:  2015-02-21       Impact factor: 4.096

Review 8.  Postmortem Toxicology of New Synthetic Opioids.

Authors:  Marta Concheiro; Rachel Chesser; Justine Pardi; Gail Cooper
Journal:  Front Pharmacol       Date:  2018-10-26       Impact factor: 5.810

9.  Mapping novel psychoactive substances policy in the EU: The case of Portugal, the Netherlands, Czech Republic, Poland, the United Kingdom and Sweden.

Authors:  Jessica Neicun; Marthe Steenhuizen; Robin van Kessel; Justin C Yang; Attilio Negri; Katarzyna Czabanowska; Ornella Corazza; Andres Roman-Urrestarazu
Journal:  PLoS One       Date:  2019-06-26       Impact factor: 3.240

10.  Effect of -NBOMe Compounds on Sensorimotor, Motor, and Prepulse Inhibition Responses in Mice in Comparison With the 2C Analogs and Lysergic Acid Diethylamide: From Preclinical Evidence to Forensic Implication in Driving Under the Influence of Drugs.

Authors:  Micaela Tirri; Sabrine Bilel; Raffaella Arfè; Giorgia Corli; Beatrice Marchetti; Tatiana Bernardi; Federica Boccuto; Giovanni Serpelloni; Francesco Botrè; Fabio De-Giorgio; Krystyna Golembiowska; Matteo Marti
Journal:  Front Psychiatry       Date:  2022-04-21       Impact factor: 5.435

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.